The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AKRO | +87.03% | +104.92% | +15.41% | +194% |
| S&P | +16.9% | +95.99% | +14.39% | +130% |
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
The biotech will soon have a new owner.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 100.0% |
| Market Cap | $4.25B | 162.2% |
| Market Cap / Employee | $63.49M | 0.0% |
| Employees | 67 | 0.0% |
| Net Income | -$70.51M | -25.9% |
| EBITDA | -$80.87M | -23.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $220.45M | -29.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $22.53M | -36.8% |
| Short Term Debt | $14.66M | 2230.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -28.77% | -2.1% |
| Return On Invested Capital | -36.38% | 0.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$48.25M | 16.0% |
| Operating Free Cash Flow | -$48.25M | 16.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.49 | 2.62 | 3.91 | 3.92 | 104.62% |
| Price to Tangible Book Value | 2.49 | 2.62 | 3.91 | 3.92 | 104.62% |
| Enterprise Value to EBITDA | -16.05 | -16.11 | -31.33 | -45.20 | 230.69% |
| Return on Equity | -35.9% | -39.2% | -27.9% | -31.1% | 7.86% |
| Total Debt | $36.36M | $36.12M | $36.57M | $37.19M | 2.54% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
